Home » Regional Blog & News » Melanoma study: are two therapies better than one?
Melanoma study: are two therapies better than one?
September 10, 2020 Earle A. Chiles Research Institute
The incidence of melanoma is increasing faster than other skin cancers. Although surgery can cure early stage melanomas, and many new standard therapies for advanced disease improve survival, few are cured. Innovation is needed to cure more patients. Providence Cancer Institute is one of 13 centers in the world, and one of four centers in the United States, to offer a new phase II study combining oncolytic viral therapy and checkpoint immunotherapy for advanced melanoma.
The randomized study will evaluate the safety and effectiveness of pembrolizumab given alone or in combination with coxsackievirus A21, an oncolytic enterovirus administered intratumorally or intraveneously, in patients with advanced or metastatic melanoma who have not received a PD-L1 immune checkpoint inhibitor.
View the study here:
A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma
Pembrolizumab (Keytruda) is an FDA-approved PD-1/PD-L1 immune checkpoint inhibitor shown to improve survival in patients with metastatic melanoma. Coxsackievirus A21 (V937), also known as CVA21, is a novel, nongenetically-modified form of a common cold virus. When administered, CVA21 targets and binds to a protein called ICAM-1, which is overexpressed on the surfaces of many cancer cells, including melanoma. After binding, CVA21 enters the melanoma cell, replicates and causes the melanoma cell to burst, releasing proteins that can help to broaden an immune response.
Brendan Curti, M.D., medical oncologist and director of Providence Melanoma Program and Genitourinary Oncology Research, is a principal investigator of the study. The purpose of the study is to determine whether the combination of pembrolizumab and CVA21 is more effective than pembrolizumab alone for treating melanoma that has spread or is unable to be removed by surgery.
Prior studies of CVA21 led by Dr. Curti and colleagues showed promising antitumor activity in patients with advanced melanoma and patients with advanced lung or bladder cancers when combined with checkpoint immunotherapies.
For more information or to refer patients to this study, please call our Clinical Research office at 503-215-2614 or submit a referral form.
More skin cancer studies
The melanoma study is among 10 clinical trials open at Providence Cancer Institute for patients with skin cancer. See all skin cancer studies.
New research studies are added frequently. Please visit our website to see all studies in all cancer types at Providence Cancer Institute.
Leaders in melanoma research and treatment
Providence Cancer Institute has been an international leader in melanoma research and treatment for more than 25 years. Some highlights of our program and contributions include:
Providence Cancer Institute researchers led the international study leading to FDA approval of ipilimumab (Yervoy), the first immunotherapy to show a survival benefit in advanced melanoma.
Providence also participated in clinical trials leading to FDA approval of nivolumab (Opdivo) and pembrolizumab (Keytruda), which offer improved response and survival benefits as second- or third-line therapies for patients with metastatic melanoma.
Providence is one of the top five high-dose Interleukin-2 (IL-2) centers in the country and is an innovator in the use of IL-2 in conjunction with high-dose per fraction radiation and the clinical development of engineered cytokines.
Providence is one of the few centers developing adoptive cell transfer including tumor infiltrating lymphocyte (TIL) and engineered T cell therapy in combination with IL-2 for patients with melanoma and other solid tumors.
Learn more about Providence Cancer Institute Melanoma Program.
The right place, the right time
The Bariatric Wellness Center at Providence Little Company of Mary guides patients through the weight-loss ...
The importance of heart health – especially now
Q&A with Cardiologist Nazanin Azadi, MD
Plant-based diet and your gut health. Is there a link?
Registered Dietician Nutritionists at Providence Little Company of Mary Medical Center San Pedro discuss the plant-based diet trend and its important role in supporting the immune system.
Providence leaders announced that it Providence will lean on technology to help recover from the financial damage caused by the pandemic.
Strengthening partnerships and advancing health in unprecedented times
Providence president and CEO, Rod Hochman, M.D., assumes his role as chair of the American Hospital Board of Trustees in the new year.
What to expect for health system IT teams in 2021, with Providence's B.J. Moore
Providence's CIO, B.J. Moore, spoke with Becker's Hospital Review on how he sees the CIO role changing in the upcoming year.
Bariatric surgery program receives accreditation
Providence Little Company of Mary's Bariatric Wellness Center is proud to have achieved the Metabolic & Bariatric Surgery Accreditation & Quality Improvement Program (MBSAQIP®) designation.
Providence's Rod Hochman, M.D. assumes role as board chair of the American Hospital Association
Rod Hochman, M.D., president and CEO, moved into his role as the American Hospital Association's (AHA) board chair for 2021.
St. Joseph Health, Humboldt County Chief Executive, Roberta Luskin-Hawk, MD, Addresses Caregivers with Important Video Message
Eureka, CA (September 14, 2018) – Roberta Luskin-Hawk, MD, Chief Executive, speaks to caregivers in regards to recent changes announced last week and offers an invitation to work collaboratively to me
St. Joseph Health, Queen of the Valley Medical Center Earns Blue Distinction® Center+ Designation for Quality in Knee and Hip Replacement S
St. Joseph Health, Queen of the Valley Medical Center is excited to announce that Blue Shield of California has recognized the hospital as a Blue Distinction Center+ for Knee and Hip Replacement, pa
Statement regarding novel coronavirus, Covid-19
Both patients, who were being monitored at the hospital for the novel coronavirus, COVID-19, have been treated and transferred to another location; coordinated by the CDC. 2/24/19 at 10 a.m. Both pa
Renovated Chapel Reopens with a Blessing at The Queen
Queen of the Valley Medical Center reopened its recently renovated chapel, and community members, volunteers and caregivers attended a blessing and celebratory mass with Fathers Fred Kutubebi and Va
Queen of the Valley Ranks Among Top 5 Percent of U.S. Hospitals for Clinical Outcomes; Named one of Healthgrades 2020 America's 250 Best Ho
St. Joseph Health, Queen of the Valley Medical Center has achieved the Healthgrades America's 250 Best Hospitals Award™ for the second consecutive year, placing the hospital in the top 5 percent of
New Robotic-Arm Assisted Knee Replacement Surgery Available at Queen of the Valley
St. Joseph Health, Queen of the Valley Medical Center is excited to announce it has launched a new, innovative robotic option for knee replacement surgery as part of its orthopedics program. On Tuesda
High School Students Attended "Robotics Career Day" at Local Hospital
On Wednesday, February 12, more than 75 high school juniors and seniors who are interested in exploring a career in health care, computer science or robotic technology attended a Career Day at Queen
St. Joseph Health Statement regarding Attorney General JOC decision
On October 31st, the Office of the Attorney General within the California Department of Justice (CA DOJ) issued a letter denying the proposed joint operating company between Adventist Health System
St. Joseph Health, Queen of the Valley Ranked in Healthgrades America's 250 Best Hospitals™ list.
St. Joseph Health, Queen of the Valley recently ranked in Healthgrades America's 250 Best Hospitals™ list. The list is based on providing exceptional quality outcomes for 32 conditions and procedures.
St. Joseph Health Hospitals in Northern California Recognized as High Performing by US News & World Report
Four St. Joseph Health hospitals in Northern California were recognized by US News & World Report as High Performing for their performance in treating a variety of commonly occurring conditions and
Statement regarding Wednesday November 20 NUHW One-Day Strike
On Friday, November 8, we received notice that the National Union of Healthcare Workers (NUHW)—a union representing our technical and service workers—plans to strike at Queen of the Valley Medical C
Queen of the Valley Medical Center Remains Open During Strike
Queen of the Valley Medical Center received notice from the National Union of Healthcare Workers (NUHW)—a union representing 470 service and technical workers—that it plans to conduct a 24-hour strike
Price Simms Family Dealership Donates $50,000 to Queen of the Valley Foundation
Queen of the Valley Foundation recently announced the launch of its Distinguish Corporate Partners program and the confirmation of Price Simms Family Dealerships as a $50,000 partner.
New Therapy Speeds Up Cancer Treatments, Reduces Side Effects
Queen of the Valley Medical Center is proud to announce that it has purchased an upgraded Elekta Infinity® linear accelerator—a device used to provide radiation treatment to cancer patients—that has